Moxifloxacin

Moxifloxacin

• CAS Number: 151096-09-2
• UNSPSC Description: Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
• Target Antigen: Antibiotic; Bacterial
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection; Cancer
• Assay Protocol: https://www.medchemexpress.com/moxifloxacin.html
• Purity: 99.72
• Solubility: DMSO : 31.25 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3OC)C1=O)O
• Molecular Weight: 401.43
• References & Citations: [1]Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88.|[2]Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39.|[3]Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702.|[4]Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.ACS Chem Biol. 2021 Dec 15.|Antibiotics (Basel). 2022, 11(2), 192.|bioRxiv. 2024 Nov 06.|Infect Drug Resist. 2021 Sep 14;14:3729-3736.|Nat Commun. 2022 Mar 2;13(1):1116.|Nat Microbiol. 2023 Mar;8(3):410-423.|Cell Mol Life Sci. 2022 Jul 22;79(8):441.|Universität zu Lübeck. Klinik für Dermatologie, Allergologie und Venerologie.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched